Tang Capital Boosts Stake in Aurinia Pharmaceuticals—Owns 10% After $3.1 Million Stock Purchase
Market Chameleon (Thu, 4-Jun 7:49 AM ET)
Business Wire (Thu, 4-Jun 7:00 AM ET)
Tang Capital takes 10% stake in Aurinia Pharma
Seeking Alpha News (Wed, 3-Jun 3:54 AM ET)
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.
PRNewswire (Wed, 3-Jun 12:44 AM ET)
Market Chameleon (Thu, 7-May 5:18 AM ET)
Business Wire (Thu, 7-May 8:00 AM ET)
Business Wire (Mon, 30-Mar 8:00 AM ET)
MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition
Business Wire (Mon, 23-Mar 11:00 AM ET)
Aurinia Announces Management Transition
Business Wire (Mon, 23-Mar 8:00 AM ET)
Aurinia Sets November 4 for Earnings Reveal—Investors Eye Business Update as New Therapies Advance
Market Chameleon (Tue, 4-Nov 5:41 AM ET)
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol AUPH.
As of June 5, 2026, AUPH stock price climbed to $16.50 with 125,194 million shares trading.
AUPH has a beta of 0.11, meaning it tends to be less sensitive to market movements. AUPH has a correlation of 0.00 to the broad based SPY ETF.
AUPH has a market cap of $2.12 billion. This is considered a Mid Cap stock.
Last quarter Aurinia Pharmaceuticals - Common Shares reported $78 million in Revenue and $.25 earnings per share. This beat revenue expectation by $642,032 and exceeded earnings estimates by $.06.
In the last 3 years, AUPH traded as high as $16.88 and as low as $4.71.
The top ETF exchange traded funds that AUPH belongs to (by Net Assets): IWM, IWO, IBB, VTWO, JSMD.
AUPH has outperformed the market in the last year with a price return of +106.5% while the SPY ETF gained +27.2%. However, in the short term, AUPH had mixed performance relative to the market. It has underperformed in the last 3 months, returning +9.7% vs +9.8% return in SPY. But in the last 2 weeks, AUPH shares have fared better than the market returning +6.8% compared to SPY +1.1%.
AUPH support price is $15.95 and resistance is $16.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUPH shares will trade within this expected range on the day.
